Global Oral Hypoglycemic Agents (OHAs) Market Insights and Forecast to 2031

Report ID: 1451434 | Published Date: Jan 2025 | No. of Page: 107 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Oral Hypoglycemic Agents (OHAs) Product Introduction
    1.2 Market by Type
        1.2.1 Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Sulfonylureas
        1.2.3 Metformin
        1.2.4 Thiazolidinediones
        1.2.5 Alpha-Glucosidase Inhibitors
    1.3 Market by Application
        1.3.1 Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Type 2 Diabetes Mellitus
        1.3.3 Type 1 Diabetes Mellitus
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Oral Hypoglycemic Agents (OHAs) Sales Estimates and Forecasts 2017-2028
    2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Estimates and Forecasts 2017-2028
    2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Oral Hypoglycemic Agents (OHAs) Sales by Region
        2.4.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2017-2022)
        2.4.2 Global Sales Oral Hypoglycemic Agents (OHAs) by Region (2023-2028)
    2.5 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region
        2.5.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2017-2022)
        2.5.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers
        3.1.1 Global Top Oral Hypoglycemic Agents (OHAs) Manufacturers by Sales (2017-2022)
        3.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oral Hypoglycemic Agents (OHAs) in 2021
    3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers
        3.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (2017-2022)
        3.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Oral Hypoglycemic Agents (OHAs) Revenue in 2021
    3.3 Global Oral Hypoglycemic Agents (OHAs) Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Oral Hypoglycemic Agents (OHAs) Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type
        4.1.1 Global Oral Hypoglycemic Agents (OHAs) Historical Sales by Type (2017-2022)
        4.1.2 Global Oral Hypoglycemic Agents (OHAs) Forecasted Sales by Type (2023-2028)
        4.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    4.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type
        4.2.1 Global Oral Hypoglycemic Agents (OHAs) Historical Revenue by Type (2017-2022)
        4.2.2 Global Oral Hypoglycemic Agents (OHAs) Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    4.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type
        4.3.1 Global Oral Hypoglycemic Agents (OHAs) Price by Type (2017-2022)
        4.3.2 Global Oral Hypoglycemic Agents (OHAs) Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application
        5.1.1 Global Oral Hypoglycemic Agents (OHAs) Historical Sales by Application (2017-2022)
        5.1.2 Global Oral Hypoglycemic Agents (OHAs) Forecasted Sales by Application (2023-2028)
        5.1.3 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    5.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application
        5.2.1 Global Oral Hypoglycemic Agents (OHAs) Historical Revenue by Application (2017-2022)
        5.2.2 Global Oral Hypoglycemic Agents (OHAs) Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    5.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application
        5.3.1 Global Oral Hypoglycemic Agents (OHAs) Price by Application (2017-2022)
        5.3.2 Global Oral Hypoglycemic Agents (OHAs) Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Oral Hypoglycemic Agents (OHAs) Market Size by Type
        6.1.1 North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2028)
        6.1.2 North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2028)
    6.2 North America Oral Hypoglycemic Agents (OHAs) Market Size by Application
        6.2.1 North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2028)
        6.2.2 North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2028)
    6.3 North America Oral Hypoglycemic Agents (OHAs) Market Size by Country
        6.3.1 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2028)
        6.3.2 North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Type
        7.1.1 Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2028)
        7.1.2 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2028)
    7.2 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Application
        7.2.1 Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2028)
        7.2.2 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2028)
    7.3 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Country
        7.3.1 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2028)
        7.3.2 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Type
        8.1.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2028)
        8.1.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2028)
    8.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Application
        8.2.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2028)
        8.2.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2028)
    8.3 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Region
        8.3.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2017-2028)
        8.3.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Oral Hypoglycemic Agents (OHAs) Market Size by Type
        9.1.1 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2028)
        9.1.2 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2028)
    9.2 Latin America Oral Hypoglycemic Agents (OHAs) Market Size by Application
        9.2.1 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2028)
        9.2.2 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2028)
    9.3 Latin America Oral Hypoglycemic Agents (OHAs) Market Size by Country
        9.3.1 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2028)
        9.3.2 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Type
        10.1.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2028)
    10.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Application
        10.2.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2028)
    10.3 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Country
        10.3.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Pfizer
        11.1.1 Pfizer Corporation Information
        11.1.2 Pfizer Overview
        11.1.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Pfizer Recent Developments
    11.2 GlaxoSmithKline
        11.2.1 GlaxoSmithKline Corporation Information
        11.2.2 GlaxoSmithKline Overview
        11.2.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 GlaxoSmithKline Recent Developments
    11.3 Bayer
        11.3.1 Bayer Corporation Information
        11.3.2 Bayer Overview
        11.3.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Bayer Recent Developments
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Corporation Information
        11.4.2 Bristol-Myers Squibb Overview
        11.4.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Bristol-Myers Squibb Recent Developments
    11.5 Novonordisk
        11.5.1 Novonordisk Corporation Information
        11.5.2 Novonordisk Overview
        11.5.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Novonordisk Recent Developments
    11.6 Sanofi-Aventis
        11.6.1 Sanofi-Aventis Corporation Information
        11.6.2 Sanofi-Aventis Overview
        11.6.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Sanofi-Aventis Recent Developments
    11.7 Servier
        11.7.1 Servier Corporation Information
        11.7.2 Servier Overview
        11.7.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Servier Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Servier Recent Developments
    11.8 Huadong Medicine
        11.8.1 Huadong Medicine Corporation Information
        11.8.2 Huadong Medicine Overview
        11.8.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Huadong Medicine Recent Developments
    11.9 Wanbang Biopharmaceuticals
        11.9.1 Wanbang Biopharmaceuticals Corporation Information
        11.9.2 Wanbang Biopharmaceuticals Overview
        11.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Wanbang Biopharmaceuticals Recent Developments
    11.10 Double-Crane Pharmaceutical
        11.10.1 Double-Crane Pharmaceutical Corporation Information
        11.10.2 Double-Crane Pharmaceutical Overview
        11.10.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Double-Crane Pharmaceutical Recent Developments
    11.11 Guangzhou Pharmaceutical
        11.11.1 Guangzhou Pharmaceutical Corporation Information
        11.11.2 Guangzhou Pharmaceutical Overview
        11.11.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Guangzhou Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Oral Hypoglycemic Agents (OHAs) Industry Chain Analysis
    12.2 Oral Hypoglycemic Agents (OHAs) Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Oral Hypoglycemic Agents (OHAs) Production Mode & Process
    12.4 Oral Hypoglycemic Agents (OHAs) Sales and Marketing
        12.4.1 Oral Hypoglycemic Agents (OHAs) Sales Channels
        12.4.2 Oral Hypoglycemic Agents (OHAs) Distributors
    12.5 Oral Hypoglycemic Agents (OHAs) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Oral Hypoglycemic Agents (OHAs) Industry Trends
    13.2 Oral Hypoglycemic Agents (OHAs) Market Drivers
    13.3 Oral Hypoglycemic Agents (OHAs) Market Challenges
    13.4 Oral Hypoglycemic Agents (OHAs) Market Restraints
14 Key Findings in The Global Oral Hypoglycemic Agents (OHAs) Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Sulfonylureas
    Table 3. Major Manufacturers of Metformin
    Table 4. Major Manufacturers of Thiazolidinediones
    Table 5. Major Manufacturers of Alpha-Glucosidase Inhibitors
    Table 6. Global Oral Hypoglycemic Agents (OHAs) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2017-2022) & (K MT)
    Table 9. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2017-2022)
    Table 10. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2023-2028) & (K MT)
    Table 11. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2023-2028)
    Table 12. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2017-2022)
    Table 14. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2023-2028)
    Table 16. Global Oral Hypoglycemic Agents (OHAs) Sales by Manufacturers (2017-2022) & (K MT)
    Table 17. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Manufacturers (2017-2022)
    Table 18. Global Oral Hypoglycemic Agents (OHAs) Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Manufacturers (2017-2022)
    Table 20. Oral Hypoglycemic Agents (OHAs) Price by Manufacturers (2017-2022) &(USD/MT)
    Table 21. Global Oral Hypoglycemic Agents (OHAs) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Oral Hypoglycemic Agents (OHAs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Agents (OHAs) as of 2021)
    Table 23. Oral Hypoglycemic Agents (OHAs) Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Oral Hypoglycemic Agents (OHAs) Product Offered
    Table 25. Date of Manufacturers Enter into Oral Hypoglycemic Agents (OHAs) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 28. Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 29. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2017-2022)
    Table 30. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Type (2023-2028)
    Table 31. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2017-2022)
    Table 34. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2023-2028)
    Table 35. Oral Hypoglycemic Agents (OHAs) Price by Type (2017-2022) & (USD/MT)
    Table 36. Global Oral Hypoglycemic Agents (OHAs) Price Forecast by Type (2023-2028) & (USD/MT)
    Table 37. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 38. Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 39. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2017-2022)
    Table 40. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Application (2023-2028)
    Table 41. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2017-2022)
    Table 44. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2023-2028)
    Table 45. Oral Hypoglycemic Agents (OHAs) Price by Application (2017-2022) & (USD/MT)
    Table 46. Global Oral Hypoglycemic Agents (OHAs) Price Forecast by Application (2023-2028) & (USD/MT)
    Table 47. North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 48. North America Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 49. North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 52. North America Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 53. North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2022) & (K MT)
    Table 56. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2023-2028) & (K MT)
    Table 57. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 60. Europe Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 61. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 64. Europe Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 65. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2022) & (K MT)
    Table 68. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2023-2028) & (K MT)
    Table 69. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 72. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 73. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 76. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 77. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2017-2022) & (K MT)
    Table 80. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2023-2028) & (K MT)
    Table 81. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 84. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 85. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 88. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 89. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2022) & (K MT)
    Table 92. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2023-2028) & (K MT)
    Table 93. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Type (2017-2022) & (K MT)
    Table 96. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Type (2023-2028) & (K MT)
    Table 97. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Application (2017-2022) & (K MT)
    Table 100. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Application (2023-2028) & (K MT)
    Table 101. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2017-2022) & (K MT)
    Table 104. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2023-2028) & (K MT)
    Table 105. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Pfizer Corporation Information
    Table 108. Pfizer Description and Major Businesses
    Table 109. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 110. Pfizer Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Pfizer Recent Developments
    Table 112. GlaxoSmithKline Corporation Information
    Table 113. GlaxoSmithKline Description and Major Businesses
    Table 114. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 115. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. GlaxoSmithKline Recent Developments
    Table 117. Bayer Corporation Information
    Table 118. Bayer Description and Major Businesses
    Table 119. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 120. Bayer Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Bayer Recent Developments
    Table 122. Bristol-Myers Squibb Corporation Information
    Table 123. Bristol-Myers Squibb Description and Major Businesses
    Table 124. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 125. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Bristol-Myers Squibb Recent Developments
    Table 127. Novonordisk Corporation Information
    Table 128. Novonordisk Description and Major Businesses
    Table 129. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 130. Novonordisk Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Novonordisk Recent Developments
    Table 132. Sanofi-Aventis Corporation Information
    Table 133. Sanofi-Aventis Description and Major Businesses
    Table 134. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 135. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Sanofi-Aventis Recent Developments
    Table 137. Servier Corporation Information
    Table 138. Servier Description and Major Businesses
    Table 139. Servier Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 140. Servier Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Servier Recent Developments
    Table 142. Huadong Medicine Corporation Information
    Table 143. Huadong Medicine Description and Major Businesses
    Table 144. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 145. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Huadong Medicine Recent Developments
    Table 147. Wanbang Biopharmaceuticals Corporation Information
    Table 148. Wanbang Biopharmaceuticals Description and Major Businesses
    Table 149. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 150. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. Wanbang Biopharmaceuticals Recent Developments
    Table 152. Double-Crane Pharmaceutical Corporation Information
    Table 153. Double-Crane Pharmaceutical Description and Major Businesses
    Table 154. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 155. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Double-Crane Pharmaceutical Recent Developments
    Table 157. Guangzhou Pharmaceutical Corporation Information
    Table 158. Guangzhou Pharmaceutical Description and Major Businesses
    Table 159. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 160. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. Guangzhou Pharmaceutical Recent Developments
    Table 162. Key Raw Materials Lists
    Table 163. Raw Materials Key Suppliers Lists
    Table 164. Oral Hypoglycemic Agents (OHAs) Distributors List
    Table 165. Oral Hypoglycemic Agents (OHAs) Customers List
    Table 166. Oral Hypoglycemic Agents (OHAs) Market Trends
    Table 167. Oral Hypoglycemic Agents (OHAs) Market Drivers
    Table 168. Oral Hypoglycemic Agents (OHAs) Market Challenges
    Table 169. Oral Hypoglycemic Agents (OHAs) Market Restraints
    Table 170. Research Programs/Design for This Report
    Table 171. Key Data Information from Secondary Sources
    Table 172. Key Data Information from Primary Sources
List of Figures
    Figure 1. Oral Hypoglycemic Agents (OHAs) Product Picture
    Figure 3. Global Oral Hypoglycemic Agents (OHAs) Market Share by Type in 2021 & 2028
    Figure 3. Sulfonylureas Product Picture
    Figure 4. Metformin Product Picture
    Figure 5. Thiazolidinediones Product Picture
    Figure 6. Alpha-Glucosidase Inhibitors Product Picture
    Figure 7. Global Oral Hypoglycemic Agents (OHAs) Market Share by Application in 2021 & 2028
    Figure 8. Type 2 Diabetes Mellitus
    Figure 9. Type 1 Diabetes Mellitus
    Figure 10. Oral Hypoglycemic Agents (OHAs) Report Years Considered
    Figure 11. Global Oral Hypoglycemic Agents (OHAs) Sales 2017-2028 (K MT)
    Figure 12. Global Oral Hypoglycemic Agents (OHAs) Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Oral Hypoglycemic Agents (OHAs) Revenue 2017-2028 (US$ Million)
    Figure 14. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 15. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2017-2022)
    Figure 16. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2023-2028)
    Figure 17. North America Oral Hypoglycemic Agents (OHAs) Sales YoY (2017-2028) & (K MT)
    Figure 18. North America Oral Hypoglycemic Agents (OHAs) Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Europe Oral Hypoglycemic Agents (OHAs) Sales YoY (2017-2028) & (K MT)
    Figure 20. Europe Oral Hypoglycemic Agents (OHAs) Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Asia-Pacific Oral Hypoglycemic Agents (OHAs) Sales YoY (2017-2028) & (K MT)
    Figure 22. Asia-Pacific Oral Hypoglycemic Agents (OHAs) Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Latin America Oral Hypoglycemic Agents (OHAs) Sales YoY (2017-2028) & (K MT)
    Figure 24. Latin America Oral Hypoglycemic Agents (OHAs) Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Sales YoY (2017-2028) & (K MT)
    Figure 26. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. The Oral Hypoglycemic Agents (OHAs) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 28. The Top 5 and 10 Largest Manufacturers of Oral Hypoglycemic Agents (OHAs) in the World: Market Share by Oral Hypoglycemic Agents (OHAs) Revenue in 2021
    Figure 29. Global Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 30. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 31. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 32. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 33. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 34. North America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 35. North America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 36. North America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 37. North America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 38. North America Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2017-2028)
    Figure 39. North America Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2017-2028)
    Figure 40. U.S. Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 41. Canada Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 42. Europe Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 43. Europe Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 44. Europe Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 45. Europe Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 46. Europe Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2017-2028)
    Figure 47. Europe Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2017-2028)
    Figure 48. Germany Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 49. France Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 50. U.K. Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 51. Italy Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 52. Russia Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 53. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Share by Region (2017-2028)
    Figure 58. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue Share by Region (2017-2028)
    Figure 59. China Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 60. Japan Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 61. South Korea Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 62. India Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 63. Australia Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 64. Taiwan Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 65. Indonesia Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 66. Thailand Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 67. Malaysia Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 68. Philippines Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 72. Latin America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 73. Latin America Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2017-2028)
    Figure 74. Latin America Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2017-2028)
    Figure 75. Mexico Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Share by Country (2017-2028)
    Figure 84. Turkey Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 86. UAE Oral Hypoglycemic Agents (OHAs) Revenue (2017-2028) & (US$ Million)
    Figure 87. Oral Hypoglycemic Agents (OHAs) Value Chain
    Figure 88. Oral Hypoglycemic Agents (OHAs) Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
GlaxoSmithKline
Bayer
Bristol-Myers Squibb
Novonordisk
Sanofi-Aventis
Servier
Huadong Medicine
Wanbang Biopharmaceuticals
Double-Crane Pharmaceutical
Guangzhou Pharmaceutical
Frequently Asked Questions
Oral Hypoglycemic Agents (OHAs) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Oral Hypoglycemic Agents (OHAs) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Oral Hypoglycemic Agents (OHAs) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports